How Honeybrains Biotech partnered with Brainify.AI to identify treatment responders and improve clinical trial outcomes using our EEG Foundational Model.
Honeybrains Biotech is a U.S.-based life science company focused on treating anxiety-related disorders such as Panic Disorder and PTSD. The company is conducting a Phase 2 Clinical Trial of their novel HB-1 compound aimed at treatment of PTSD.
The challenge: proving clinical efficacy in the face of biological heterogeneity. In recent years, numerous psychiatric drugs have failed in clinical trials—not because the compounds lack therapeutic potential, but because they are evaluated across broad, heterogeneous patient populations.
Many promising therapies appear ineffective at the population level, even though they may be highly effective for specific subgroups.
Brainify.AI was engaged to address this challenge with a tailored biomarker solution leveraging our EEG Foundational Model.
Design protocols including scales, ERP (event-related potential) tasks, and standardized procedures for biomarker discovery
Install, verify, and test EEG/ERP hardware and software to ensure readiness for data collection
Conduct day-to-day EEG acquisition at clinical sites by trained Brainify.AI technicians
Leverage Brainify.AI's EEG Foundational Model, trained on 150,000+ subjects, for biomarker discovery and validation
Implement the biomarker on Brainify.AI's neurotech platform for clinical practice use
Brainify.AI's EEG Foundational Model is trained on an extensive dataset (over 150,000 subjects), enabling it to recognize complex, generalized patterns associated with neuropsychiatric disorders.
The EEG Foundational Model serves as a versatile basis from which specific biomarkers for various psychiatric conditions and treatments can be derived, significantly reducing time and costs.
The model allows for precise prediction of treatment and placebo responses, greatly increasing the likelihood of clinical trial success.
Objective Biomarkers
EEG provides objective neurophysiological biomarkers that measure brain activity directly.
Non-invasive & Scalable
EEG procedures are non-invasive, relatively low-cost, and practical for widespread implementation.
By incorporating EEG-based biomarkers, particularly for placebo response prediction, ensuring clearer differentiation of HB-1's efficacy versus placebo.
With validated EEG biomarkers serving as companion diagnostics (CDx), HB-1 could potentially be elevated from fourth- or fifth-line treatments to second- or third-line options.
Substantially reduce overall clinical trial costs by minimizing required sample sizes and enhancing statistical power without compromising trial quality.
Objective neurophysiological measures can support an efficacy narrative alongside clinical scales. Regulatory acceptance depends on the sponsor’s data and FDA’s review.